GlobalData on MSN19h
Sarepta and Roche aim to resume paused Elevidys trials following patient death
Sarepta and Roche announced a 16-year-old US patient dosed with the gene therapy died of acute liver failure in March 2025.
Sarepta price target lowered to $184 from $215 at Oppenheimer
Oppenheimer analyst Andreas Argyrides lowered the firm’s price target on Sarepta (SRPT) to $184 from $215 and keeps an Outperform rating on the ...
4 Beaten-Down Stocks That Could Skyrocket by 50% to 543%, According to Wall Street
As biotech investors know, companies in the industry can sometimes earn significant returns in relatively short periods, like a year, thanks to excellent clinical or regulatory progress. And based on ...
3 To Know: Egg prices drop; as do some drug stocks; car makers urge speed-up
National egg prices fell 9 percent to an average of $3 a dozen, according to the U.S. Department of Agriculture.
LPL Financial LLC Has $6.50 Million Stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)
LPL Financial LLC grew its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 12.4% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 53,438 shares ...
PharmiWeb15h
Duchenne Muscular Dystrophy Drugs Market Size Expected to Grow at a CAGR of 10.96% Through 2034
Global Duchenne Muscular Dystrophy Drugs Market value attained USD 3.9 Billion in 2025. The market will achieve USD 6.5 ...
Amyotrophic Lateral Sclerosis Market To Surge From $0.94 Billion To $1.25 Billion By 2032, MRFR Study Reveals
Amyotrophic_Lateral_Sclerosis_Market_ MRFR reveals steady growth in the ALS market, projecting an increase from $0.94 billion in 2023 to $1 ...